Retrospective Study of Brachytherapy

NCT05242861 · tracked via the Priya Life Science China tracker

Sponsor

Zhejiang Cancer Hospital

Phase

Observational

Started

2022-02-20

Last updated

2022-02-16

Condition(s) studied

BrachytherapyUterine Cervical NeoplasmsUterine NeoplasmsVulvar CancerVaginal CancerOvarian NeoplasmsGynecologic Neoplasm

Investigational drug(s) / intervention(s)

Brachytherapy

Brachytherapy: Applicator, dose, schedule, technology, image, 3D print, efficacy, toxicity of brachytherapy

Study summary

Brachytherapy for gynecological cancers will be studied retrospectively.

Eligibility

Sex

FEMALE

Min age

18 Years

Max age

80 Years

Healthy volunteers

Inclusion Criteria: * 18 - 80 female * Underwent brachytherapy * With gynecological cancer Exclusion Criteria: * Refusal to enter this trial

Primary outcome measure(s)

Overall survival rate — 5-year
the percentage of participants in the group who survives

Trial sites (1)

Facility	City	Region	Status
Zhejiang Cancer Hospital	Hangzhou	Zhejiang	Recruiting

More Zhejiang Cancer Hospital trials in China

Thiotepa in Combination With Pirtobrutinib (a BTK Inhibitor) and Sintilimab (a PD-1 Inhibitor) for Frail or Relapsed/Refractory Primary or Secondary Central Nervous System Lymphoma Recruiting

A Phase II, Single-arm, Multicenter, Prospective Study of Cardunolizumab in Recurrent or Metastatic Vulvar and Vaginal Cancer Recruiting

Development of Novel Gastric Cancer Screening and Diagnosis Technologies Using Tongue Imaging and Study of Tongue Image Changes Mechanisms Recruiting

Research on AI Models for Predicting Breast Cancer Treatment Effectiveness to Guide Her-2 Targeted ADC Therapy Starting soon

Postoperative Analgesia Between Paravertebral Block and Epidural Block in Esophageal Surgery Recruiting

Other trials for the same condition

Adebrelimab Combined With Fuzuloparib in the Treatment of Patients With Recurrent Platinum-resistant Ovarian Cancer. Recruiting

A Phase II Study of GV20-0251 in Combination With Anti-PD-1 Monoclonal Antibodies in Patients With Unresectable, Locally Advanced, or Metastatic Solid Tumors. Starting soon

A Study of LY4337713 in Participants With FAP-Positive Solid Tumors Recruiting

Neoadjuvant Therapy in Cervical Cancer Recruiting

Patient Journey in Advanced Gynecologic Cancers Starting soon

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05242861 on ClinicalTrials.gov ↗ ← All trials in China